Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
Read time: 3 minutes. Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the...
Our meetup on Wednesday, December 17, featured guest speaker Daniel Huvard, LCSW, of MD Anderson Cancer Center, who provided tips on managing stress during the holiday season while...
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Whether you're living with lung cancer, or caring for someone with the disease, online groups and biomarker-specific communities can offer much-needed support.